Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 14, 2022; 28(22): 2509-2522
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2509
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2509
Table 1 Baseline characteristics of the study population
| Total included subjects (n = 456) | Placebo group (n = 226) | Probiotic group (n = 230) | |
| Female | 392 (86) | 190 (84.1) | 202 (87.8) |
| Age (yr) | 40.5 ± 14.26 | 39.9 ± 14.56 | 41.2 ± 13.96 |
| Abdominal pain score | 3.98 ± 1.05 | 3.98 ± 1.07 | 3.97 ± 1.04 |
| Bloating score | 4.01 ± 1.17 | 4.04 ± 1.18 | 3.99 ± 1.15 |
| Flatulence/borborygmi score | 3.64 ± 1.37 | 3.62 ± 1.46 | 3.66 ± 1.28 |
| IBS-QOL global score | 68.0 ± 17.02 | 67.2 ± 17.17 | 68.8 ± 16.86 |
- Citation: Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522
- URL: https://www.wjgnet.com/1007-9327/full/v28/i22/2509.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i22.2509